| Literature DB >> 22119854 |
Malcolm C Finlay1, Ross J Hunter, Victoria Baker, Laura Richmond, Farai Goromonzi, Glyn Thomas, Kim Rajappan, Edward Duncan, Muzahir Tayebjee, Mehul Dhinoja, Simon Sporton, Mark J Earley, Richard J Schilling.
Abstract
PURPOSE: Integration of a 3D reconstruction of the left atrium into cardiac mapping systems can aid catheter ablation of atrial fibrillation (AF). The two most widely used systems are NavX Fusion and Cartomerge. We aimed to compare the clinical efficacy of these systems in a randomised trial.Entities:
Mesh:
Year: 2011 PMID: 22119854 PMCID: PMC3305875 DOI: 10.1007/s10840-011-9632-7
Source DB: PubMed Journal: J Interv Card Electrophysiol ISSN: 1383-875X Impact factor: 1.900
Demographic and baseline factors
| Randomisation | ||||
|---|---|---|---|---|
| Cartomerge | NavX Fusion |
| ||
| Number consented | 50 | 51 | ||
| Underwent ablation | 47 | 50 | >0.9 | |
| Diagnosis | PersAF ( | 49% (23) | 50% (25) | >0.9 |
| Male | 67% | 29% | 0.66 | |
| Age at procedure | 59 (25–79) | 63 (34–71) | 0.53 | |
| Hypertension? | 41% | 44% | 0.81 | |
| Structural heart disease? | Normal | 80% | 84% | 0.73 |
| IHD | 13% | 8% | ||
| Cardiomyopathy | 7% | 8% | ||
| Rhythm at procedure start | AF | 50% | 46% | 0.72 |
| AT | 0% | 0% | ||
| Typical flutter | 4% | 2% | ||
| SR | 46% | 52% | ||
| Number of previous anti-arrhythmics | 1 | 17% | 19% | 0.72 |
| 2 | 35% | 27% | ||
| 3 | 33% | 35% | ||
| 4 | 13% | 19% | ||
| 5 | 2% | 0% | ||
| AF duration (months) | 60 (2–240) | 64 (8–306) | >0.9 | |
Fig. 1Clinical outcomes—Kaplain–Meier diagram of survival free from documented episodes of AF
Procedural outcomes
| Cartomerge | NavX Fusion |
| ||
|---|---|---|---|---|
| Procedures attempted (PersAF) | 47 (23) | 50 (25) | 0.30 | |
| Method of restoration of sinus rhythm in persAF | Ablation | 17% | 36% | 0.12 |
| DC cardioversion | 57% | 56% | ||
| Internal cardioversion | 17% | 4% | ||
| Failure of cardioversion | 9% | 0% | ||
| Rhythm at discharge | Atrial fibrillation | 2% | 0% | 0.34 |
| Atrial tachycardia | 2% | 0% | ||
| Sinus rhythm | 96% | 100% | ||
| ECG rhythm 3 month | Atrial fibrillation | 15% | 23% | 0.67 |
| Atrial tachycardia | 10% | 9% | ||
| Sinus rhythm | 74% | 67% | ||
| ECG rhythm 6 months | Atrial fibrillation | 21% | 22% | 0.91 |
| Atrial tachycardia | 13% | 10% | ||
| Sinus rhythm | 66% | 68% | ||
| Freedom from AF at 6 months without drugs ( | 51% (24) | 48% (24) | 0.76 | |
Procedural time points, fluoroscopic doses and RF times
| Cartomerge | NavX fusion |
| ||
|---|---|---|---|---|
| Mean (±SD) | Mean (±SD) | |||
| Start until completion of transseptal punctures | Time (min) | 35 (±19) | 31 (±16) | 0.24 |
| Screening (min) | 8 (±6) | 6 (±5) | 0.18 | |
| Fluoroscopic dose (mGycm2) | 821 (±1,154) | 647 (±890) | 0.42 | |
| Registration | Time (min) | 24 (±15) | 33 (±14) | 0.002 |
| Screening (min) | 11 (±7) | 15 (±7) | 0.03 | |
| Fluoroscopic dose (mGycm2) | 840 (±725) | 1,415 (±1,670) | 0.03 | |
| Isolation of RPV | Time (min) | 54 (±27) | 58 (±30) | 0.57 |
| Screening (min) | 16 (±11) | 22 (±20) | 0.08 | |
| Fluoroscopic dose (mGycm2) | 853 (±870) | 1,632 (±2,061) | 0.02 | |
| RF time (s) | 1,314 (±674) | 1,466 (±764) | 0.34 | |
| Isolation of LPV | Time (min) | 51 (±23) | 56 (±29) | 0.37 |
| Screening (min) | 11 (±8) | 12 (±13) | 0.62 | |
| Fluoroscopic dose (mGycm2) | 897 (±1,366) | 1,085 (±1,384) | 0.51 | |
| RF time (s) | 1,105 (±578) | 1,268 (±783) | 0.28 | |
| Total | Time (min) | 242 (±94) | 263 (±89) | 0.26 |
| Screening (min) | 57 (±25) | 58 (±26) | 0.79 | |
| Fluoroscopic dose (mGycm2) | 4,520 (±4,412) | 5,295 (±4,935) | 0.42 | |
| RF time (s) | 3,292 (±2,001) | 4,041 (±1,994) | 0.07 | |
| Total common procedure time (min) | 164 (±55) | 177 (±49) | 0.22 | |
Total times include times for rechecking of pulmonary veins and linear lesions, mapping for ATs and ablation for linear lesions and CFAEs in persAF
Fig. 2Key procedural time points, shown as cumulatives (rather than true order in which ablations progressed). This illustrates the contributions of each procedural stage to the overall time taken. Inset numerals show times for each stage as mean ± SD. Time from start of case to registration was significantly shorter with Cartomerge, but this did not translate into overall reduced case time. pAF paroxysmal atrial fibrillation, persAF persistent atrial fibrillation, DTSP double transseptal puncture, RPV right pulmonary vein, LPV left pulmonary vein
Lesion to CT shell distance
| Cartomerge | NavX fusion |
| |
|---|---|---|---|
| No. of patients analysed | 21 | 21 | |
| No. of lesions analysed | 3,174 | 2,712 | 0.53 |
| Mean L-CT distance (mm) | 2.0 ± 0.5 | 3.4 ± 0.9 | 0.001 |
| Mean patient maximum L-CT distance (mm) | 10.2 ± 0.7 | 15.9 ± 1.1 | 0.0002 |
Unit cost of each catheter based on company published UK list price
| Catheter | Unit cost |
|---|---|
| Quadripolar diagnostic | 1 |
| Decapolar diagnostic | 1.5 |
| Orbitor (Bard Inc.) | 10.8 |
| Optima (St Jude Medical) | 10.8 |
| Lasso (Biosense Webster) | 9.6 |
| Irrigated RF | 10.0 |
| Navistar irrigated RF | 12.3 |
| NavX pat | 8.1 |
| Ref patch Carto | 6.2 |
RF radiofrequency